Form 4: Accuray Officer's Tax Withholding on RSU Settlement

Sandeep Chalke, Accuray's SVP and Chief Commercial Officer, had 40,000 shares withheld for tax obligations related to RSU settlement.

Summary

• Sandeep Chalke, SVP, Chief Commercial Officer of Accuray Inc. (ARAY), reported a transaction involving company common stock.
• On March 31, 2026, 40,000 shares of common stock were disposed of.
• These shares were withheld by Accuray Inc. to cover tax withholding and remittance obligations associated with the net settlement of Restricted Stock Units (RSUs).
• The price per share for the withheld shares was $0.3881.
• Following this transaction, Sandeep Chalke beneficially owns 419,806 shares of Accuray Inc. common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While shares were 'disposed,' it was for tax purposes related to RSU vesting, not a discretionary sale, and the officer retains significant ownership.

Positives

• The transaction is a routine tax withholding event related to RSU vesting, not an open market sale by the officer.
• The officer retains a significant beneficial ownership of 419,806 shares after the transaction, indicating continued alignment with shareholder interests.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. This specific filing, detailing tax withholding on RSU settlement, is a common occurrence for executives receiving equity compensation and does not inherently signal a change in company fundamentals or strategic direction within the medical technology or radiation oncology industry where Accuray operates. It is distinct from open market sales or purchases that might indicate management's view on valuation.

Comparison to Industry Standards

• This transaction is a routine tax withholding event, common across all industries for executives receiving equity compensation.
• It does not provide a basis for comparison to specific company or project results, but rather reflects standard compensation practices.
• For example, executives at companies like Varian Medical Systems (now Siemens Healthineers) or Elekta AB would undergo similar tax-related share withholdings upon vesting of their equity awards.

Stakeholder Impact

• Shareholders: The transaction is a routine tax withholding and does not indicate a change in the officer's confidence in the company. The officer maintains a substantial equity stake.
• Employees: No direct impact on employees.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related transaction for an executive's equity compensation. It does not provide new fundamental information about Accuray Inc.'s operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The officer's continued significant beneficial ownership suggests ongoing alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Accuray Inc, ARAY, Form 4, Insider Transaction, Sandeep Chalke, Restricted Stock Units, RSU, Tax Withholding, Beneficial Ownership, Officer Transaction